Surviving breast cancer at 5 years | Recurrence free at 5 years | |||||
---|---|---|---|---|---|---|
Variable | n | % | p Value | n | % | p Value |
ER, oestrogen receptor; PR, progesterone receptor. | ||||||
Stage | <0.001 | <0.001 | ||||
I | 163 | 92 | 163 | 87 | ||
II | 212 | 86 | 212 | 77 | ||
III | 38 | 54 | 38 | 54 | ||
Lymph node status | <0.001 | <0.001 | ||||
Negative | 247 | 92 | 247 | 86 | ||
Positive | 166 | 77 | 166 | 68 | ||
Histological grade | 0.043 | 0.071 | ||||
I | 108 | 92 | 108 | 85 | ||
II | 192 | 85 | 192 | 78 | ||
III | 120 | 81 | 120 | 74 | ||
ER status | <0.001 | 0.124 | ||||
Positive | 323 | 89 | 323 | 80 | ||
Negative | 95 | 72 | 95 | 74 | ||
PR status | 0.001 | 0.183 | ||||
Positive | 261 | 89 | 261 | 80 | ||
Negative | 157 | 78 | 157 | 76 | ||
Nuclear p21WAF1 | 0.398 | 0.388 | ||||
Low <5% | 260 | 84 | 260 | 78 | ||
High ≥5% | 160 | 87 | 160 | 80 | ||
Nuclear p53 | 0.837 | 0.678 | ||||
Low <10% | 225 | 86 | 225 | 79 | ||
High ≥10% | 193 | 84 | 193 | 78 | ||
Combined p21/p53 | 0.461 | 0.782 | ||||
p21+/p53+ | 84 | 84 | 84 | 80 | ||
p21+/p53− | 76 | 91 | 76 | 79 | ||
p21−/p53+ | 109 | 85 | 109 | 76 | ||
p21−/p53− | 149 | 83 | 149 | 79 | ||
Cell proliferation | <0.001 | <0.001 | ||||
Low <20% | 230 | 93 | 230 | 89 | ||
High ≥20% | 184 | 75 | 184 | 64 |